glp-1 obesity drug news today 2025 Weight Loss Market Size, Share What the Obesity Drugmakers Expect

GLP-1 receptor agonist 11 | C31H31ClFN3O4 | CID 168432133 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.

Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D

Discover how naturopathy supports natural GLP-1 production and improves insulin resistance through gut health, nutrition, stress management, and lifestyle changes.

With so many people interested in using GLP-1 agonists off-label to lose a few extra pounds, what does it mean for this class of drugs?

Although rare, associations with nonarteritic anterior ischemic optic neuropathy, pancreatitis, medullary thyroid carcinoma, and acute kidney injury (AKI) have been reported, primarily through pharmacovigilance and case-based evidence